

**Acknowledgement and Consent for Disclosure of
A Waiver Under 18 U.S.C. §208(b)(3)**

Thomas Fleming, Ph.D.

Committee: Drug Safety and Risk Management Advisory
Committee

Meeting Date: February 9, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to agenda items concerning the discussion of approaches that could be used to study whether Attention Deficit Hyperactivity Disorder (ADHD) products increase the risk of adverse cardiovascular outcome. I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Unrelated Data Safety and Monitoring Committee	Affected Firm.	Earns less than \$10,001 a year.
Unrelated Data Safety and Monitoring Committee	Affected Firm.	Earns less than \$10,001 a year.

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued. The public disclosure will be accomplished by reading this statement into the record and by FDA making a written copy publicly available at the time of the meeting. I understand that without public disclosure of these interests the waiver is not valid.

 //S//
Signature of SGE

 1/3/2006
Date